By Taimour Zaman, Founder, AltFunds Global
Healthcare has emerged as one of the most resilient sectors for growth capital, drawing providers who want stability and long-term demand. For founders, the question is not whether capital exists. It is where to find providers with both sector expertise and the patience to work through regulatory, reimbursement, and technology adoption hurdles. The modern healthcare growth capital market is increasingly specialized, with funds clustering around biotech, medtech, digital health, and value-based care platforms.
The state of healthcare growth capital
The post-pandemic reset recalibrated expectations. Deal value in healthcare growth equity has come down from the 2021 peak, but median check sizes have grown and selectivity has increased. Funds are concentrating firepower in companies with proven revenue models, defensible IP, and a pathway to profitability. Three shifts define the current market:
- Digital health consolidation. After the overfunded boom of 2020 and 2021, capital now backs later-stage consolidators rather than speculative early entrants.
- Biotech rationalization. Capital shifted away from pre-clinical moonshots toward companies with late-stage pipelines.
- Value-based care. Growth equity firms favor scalable models aligned with payer incentives, such as risk-bearing provider groups.
Case study: Devoted Health
Devoted Health, a Medicare Advantage startup, illustrates how sector-focused providers deploy growth capital. In 2021 it raised $1.15 billion in a growth round led by SoftBank Vision Fund 2, alongside returning healthcare specialists including Andreessen Horowitz's bio fund and General Catalyst. The capital financed geographic expansion, technology infrastructure, and integration of care delivery. By 2023 enrollment had doubled, though margins remained thin. Backers tolerated the burn because the company demonstrated measurable cost savings and high member retention.
Where specialized healthcare growth capital lives
Healthcare-focused growth capital typically sits in four clusters:
- Dedicated healthcare growth equity funds: firms such as Deerfield Management, ARCH Venture Partners, and General Catalyst's health practice.
- Diversified growth equity firms with healthcare practices: Insight Partners, TPG Growth, Summit Partners.
- Corporate venture and growth funds run by providers, insurers, and pharma companies, such as Kaiser Permanente Ventures.
- Institutional allocators taking direct exposure: sovereign wealth funds and large pension plans selectively backing growth rounds.
Trade-offs, risks, and opportunities
- Regulatory overhang: FDA approvals and CMS reimbursement delays can derail growth timelines.
- Capital intensity: healthcare scale-ups often require larger follow-on rounds than their tech peers.
- Exit environment: IPO windows for biotech remain narrow; M&A by strategics is the dominant exit path.
- The opportunity: platforms that integrate technology with care delivery, manage chronic disease at scale, or align with value-based reimbursement remain attractive.
Conclusion
Healthcare growth capital is increasingly concentrated among providers who combine domain expertise with long-duration capital. Founders should orient toward partners who can not only write large checks but also work through the regulatory, payer, and clinical adoption environment. The play is not chasing the largest pool of money. It is aligning with specialized partners who understand the long arc of healthcare.
Building a healthcare capital file? Visit us at AltFunds Global.
Disclaimer
This article is provided for general educational and informational purposes only. It does not constitute financial, legal, or tax advice, and it is not an offer, solicitation, or recommendation to buy or sell any financial instrument. References to third-party firms are illustrative market references, not endorsements or recommendations. AltFunds Global is a global financial advisory firm; it is not a bank, lender, fund, custodian, broker-dealer, or placement agent. Readers should seek independent professional advice (legal, tax, financial) before making any decisions. Past case studies do not guarantee future results. No liability is accepted for any loss arising from the use of this material.